RemeGen Co. Ltd. Class A
688331
Classificação em ações
#2439
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Preço da ação
$14.33
Valor de mercado
$8.02B
Variação (1 dia)
1.81%
Variação (1 ano)
7.94%
País
CN
Negociar RemeGen Co. Ltd. Class A (688331)
Categoria
Healthcare
Lucros da RemeGen Co. Ltd. Class A (688331)
Lucros em Jun 2026 TTM: $843.65M
De acordo com os últimos relatórios financeiros da RemeGen Co. Ltd. Class A, os ganhos atuais da empresa são de $843.65M. Em 2023, a empresa teve ganhos de $-213.49M, uma diminuição em relação a aos ganhos de 2022, que foram de $-144.80M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da RemeGen Co. Ltd. Class A de 2018 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $843.65M | -519.37% |
| 2024 | $-201.17M | -5.77% |
| 2023 | $-213.49M | 47.44% |
| 2022 | $-144.80M | -433.15% |
| 2021 | $43.46M | -140.69% |
| 2020 | $-106.82M | 72.87% |
| 2019 | $-61.79M | 57.45% |
| 2018 | $-39.24M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | 525.25% |
US
|
|
| $-3.09B | -465.91% |
US
|
|
| $-4.02B | -576.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 131.22% |
NL
|
